Merck & Co., Inc. (MRK)

From the record

Merck & Co., Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Merck & Co., Inc.'s 10 filed years say what it did: revenue went from $40 billion in fiscal 2016 to $65 billion in fiscal 2025, up 5.6% a year; it rose in 8 of 9 years; the deepest fall was 8% from fiscal 2018 to fiscal 2019; net income was positive in 10 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Merck & Co., Inc.'s diluted share count shrank about 0.5% a year, and dividends and buybacks returned about 61% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 34 sales and 0 purchases of their own stock on the open market in the year to 2026-11-03 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Merck & Co., Inc. earned about 35 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 36 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 62 cents per dollar of assets, and net share issuance: its share count shrank 1.3% over the year (the filed statements).

From the record

Merck & Co., Inc.'s standing among 315 graded names in its industry family: revenue of $65 billion in fiscal 2025 ranks in the top 1% by size; a net margin of 28.1% ranks in the top 10%; revenue growth of 3.1% a year over the last 3 filed years ranks in the bottom 43% (its annual reports).

From the record

Merck & Co., Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Davis, Robert M (Chairman, CEO & President, as filed), filing under that title since 2022-02-28, 4.7 years (bottom 45% of its family); the 29 officers and directors filing in the last fifteen months have been on the record a median of 5.8 years (top 46%); 4 officer or director changes were reported on Form 8-K since 2023-11-13, against the 29 people in charge now (top 10%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Merck & Co., Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $15 billion against debt of $47 billion leaves -23.5% of its assets as net cash, bottom 7% of its family; cash from operations less capital spending is 19% of revenue (top 14%); a gross margin of 74.8% (top 41%); research spending of 24.3% of revenue (bottom 30%) (its annual report).

From the record

Merck & Co., Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 3.1% a year over the last three filed years against 5.6% over all 10, slowing (bottom 48% of its family); the newest year grew 1.3% (bottom 42%); research spending grew 5.2% a year (top 46%); capital spending grew -2.1% a year (top 40%) (its annual reports). Merck & Co., Inc. reported 2 lines of business in fiscal 2025: Pharmaceuticalsegment at $58 billion, Animal Healthsegment at $6.4 billion. 2 of 2 grew in the latest filed year, and the largest line is 90% of revenue (its annual report).

From the record

Merck & Co., Inc.'s newest year against its own record: revenue of $65 billion in fiscal 2025 came in 2.6% below the $67 billion its prior three years' pace pointed to (bottom 47% of its family); net income of $18 billion against a prior three-year average of $11 billion (top 24%); a net margin of 28.1% against 17.3% before (bottom 50%) (its annual reports).